【入金不要ボーナス$40】ビーベット(BeeBet)の登録方法を画像 ...

MENU Company Company Back Company Message from Top Management Our Founding Spirit Brand Statement Our Story Our History of Value Creation Vision and Strategy Framework Group Vision Long-Term Management Strategy Management Policy Medium-Term Management Plan Corporate Information and Business Sites Business Overview Introduction of Executives Corporate Governance Group Companies Procurement Policy Corporate Policy over Internal Control Integrated Report Products and Technology Products Back Products Search by Application Mobility Architectural Materials Infrastructure / General Industry Electronics Semiconductors Energy Daily commodities, Food industry Life Science Search by Business Category Architectural Glass Automotive Display Electronic Materials Essential Chemicals Performance Chemicals Life Science Ceramics New Business Search by Name Search by Keyword Technology and Innovation back Technology and Innovation A Message from the Chief Technology Officer Technology Development Strategy Intellectual Property Strategy R&D Structure Core Technologies Technology Highlights Mobility Electronics Life Science AGC Yokohama Technical Center AGC OPEN SQUARE “AO” Overview Facility Guide Access Collaboration Research Collaboration System R&D Library Measures to Prevent Misconduct in Research and Properly Manage Public Research Funds Sustainability Sustainability Back Sustainability Protecting the Global Environment and Utilizing Resources Supporting the Evolution of Cities and Mobility Realizing Longevity Society Where People Can Live in Good Health Creating a Healthy and Secure Society through Connections Generating New Value from Fair and Safe Workplaces Message from the President and CEO The AGC Group’s Sustainability Management Sustainability Promotion System Download Report Site Reports External Evaluations GRI Standards Index Sustainability-related policies, criteria, and guidelines AGC Group Code of Conduct/Compliance Help Lines Investors Investors Back Investors Management Information To Our Shareholders Vision and Strategy Framework Business Risks Disclosure Policy Financial Highlights IR News IR Library Company Overview Presentations of Financial Results Presentations of Business Briefings Financial Results Financial Review AGC Review (Newsletter for Shareholders) ESG Information Sustainability Corporate Governance Integrated Report Stock and Bond Information Stock Information Corporate Bond and Rating Information Dividend Information Analyst Coverage General Meeting of Shareholders Methods for Various Stock Procedures Electronic Public Notice Articles of Incorporation Stock Price Contact Us FAQ IR Email News Support Information IR Calendar Cautionary Statement IR Site Map Careers News Contact EN JP CN Search October 3, 2022Management Download PDF Print AGC Begins Full-scale Study to Expand its Bio-CDMO Capability in Japan ― Selected for METI's "Developing biopharmaceutical manufacturing sites to strengthen vaccine production project" ― AGC (AGC Inc.; Headquarters: Tokyo; President: Yoshinori Hirai), a world-leading manufacturer of glass, chemicals, and high-tech materials, has announced that the company has been selected on September 30 as eligible for METI's*1 "Developing biopharmaceutical manufacturing sites to strengthen vaccine production project" (hereinafter referred to as the "Subsidy Project")*2. With this selection, AGC will accelerate its expansion planning of its biopharmaceutical CDMO*3 capabilities at the AGC Yokohama Technical Center (Tsurumi-ku, Yokohama) to be operationally ready in 2025. As was the case for COVID-19, new types of vaccines utilizing biopharmaceutical technologies are being researched and developed around the world to combat new infectious diseases. Meanwhile in Japan there are limited production sites for biopharmaceuticals, including these new types of vaccines, and the development of production sites in Japan is an urgent issue. Against this backdrop, the additional capabilities AGC is considering for the AGC Yokohama Technical Center consists of CDMO services for mRNA pharmaceuticals, cell and gene therapeutics, and protein based biopharmaceuticals made using mammalian cell cultures, which also can be applied for the manufacture of vaccines in the event of a pandemic. With the Bio-CDMO know-how that the Group has cultivated at its multiple sites, Japan, the U.S., and Europe, the Group aims to early expand its services in Japan, thereby adding to the domestic biopharmaceutical development and manufacturing capacities, and a more robust production network. Under its medium-term management plan AGC plus-2023, the AGC Group has positioned its Life Science business, including biopharmaceutical CDMO services, as one of its strategic businesses and has aggressively made acquisitions and capital investments to expand this business. To date, the Group has established cGMP-compliant production sites in three regions around the world, Japan, the US, and Europe, and has also continuously adapted new technologies and modalities to meet customer needs. The AGC Group will work to provide its customers in each region with globally unified, high-quality services, contributing to customers, patients, and the wider society as a whole. Notes *1 METI: Japan’s Ministry of Economy, Trade and Industry *2 Subsidy Project: METI has established a program to secure facilities that can produce biopharmaceuticals to meet the needs of companies during normal times and switch to vaccine production during emergencies, in order to prepare for future variants and new infectious diseases.   *3 CDMO: Contract Development & Manufacturing Organization. A company which is contracted on behalf of another company to serve product manufacturing as well as the development of manufacturing processes. REFERENCE The AGC Group’s CDMO business locations Media inquiries Chikako Ogawa, General Manager, Corporate Communications & Investor Relations DivisionAGC Inc. Contact: Nakao TEL: +81-3-3218-5603 Contact form Share News Index HomeNewsAGC Begins Full-scale Study to Expand its Bio-CDMO Capability in Japan Check in AGC Site Map About Social Media Contact About This Site Privacy Policy ©AGC Inc.